Dr. David Harper is the Chief Executive Officer of Evolution Biotechnologies. With a strong scientific background in virology and microbiology, Dr. Harper is the author of over seventy works in the area and has broad experience of managing research programmes in a variety of settings and of directing the work of staff both internally and through external contractors.
Dr. Harper holds a B.Sc. in Microbiology and Virology from the University of Warwick, and a Ph.D. in Viral Genetics from the University of Newcastle-upon-Tyne, and is an alumnus of the University of Iowa.
As the founder, CEO and CSO of Biocontrol Limited and CSO of AmpliPhi Biosciences Dr. Harper managed the first modern regulated clinical trial to demonstrate the efficacy of bacteriophages to be conducted anywhere in the world. This skillset is key to the work of Evolution Biotechnologies.
Dr. Harper has experience of the many commercial and scientific stages required for the planned work. This experience of managing the growth of a start-up biotechnology company through to global operations with a public listing underpins the potential of Evolution Biotechnologies.
Dr. Harper is a named inventor on multiple patents with wide experience of the generation and management of intellectual property portfolios, and has extensive experience of recruiting non-dilutive grant funding.